PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/655,861	
l IN	NFORMATION	I DI	SCLOSURE	Filing Date	September 5, 2003	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Yi Wang	
				Art Unit	1644	
	(Use as many she	eets as	s necessary)	Examiner Name	P. Gambel	
Sheet	1	of	2	Attorney Docket Number	ALXN-P01-102	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan	
Initials*	No. ¹	Number-Kind Code Code	WIWI-DD-1111	Applicant of Cited Document	Figures Appear	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶	
		WO 95/29697	11-09-1995	Alexion Pharmaceuticals, Inc.			

Examiner	/Phillip Gambel/	Date	10/05/2011
Signature	/Filling Garribei/	Considered	10,00,110.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

10655861 - GAU: 1644

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449/PTO			Complete if Known	
				Application Number	10/655,861
l IN	IFORMATION	1 DI	SCLOSURE	Filing Date	September 5, 2003
STATEMENT BY APPLICANT				First Named Inventor	Yi Wang
				Art Unit	1644
(Use as many sheets as necessary)				Examiner Name	P. Gambel
Sheet	2	of	2	Attorney Docket Number	ALXN-P01-102

r Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published.			
	Kaplan, Mariana, "Eculizumab," Current Opinion in Investigational Drugs, Vol. 3(7); pp. 1017-1023 (2002).		
	Moongkarndi et al., "Immunological and functional properties of two monoclonal antibodies against human C5," Immunobiol. Vol. 165, page 323 (1983).		
	Moongkarndi et al., "Monoclonal antibodies against the fifth component of human complement," Immunobiol, Vol 162; page 397 (1982).		
	Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug, Press Release dated January 13, 2004.		
		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Kaplan, Mariana, "Eculizumab," Current Opinion in Investigational Drugs, Vol. 3(7); pp. 1017-1023 (2002). Moongkarndi et al., "Immunological and functional properties of two monoclonal antibodies against human C5," Immunobiol. Vol. 165, page 323 (1983). Moongkarndi et al., "Monoclonal antibodies against the fifth component of human complement," Immunobiol, Vol 162; page 397 (1982). Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug, Press Release dated	

Examiner Signature	/Phillip Gambel/	Date Considered	10/05/2011
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.